Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Can-Fite Biopharma Ltd ADR
(NY:
CANF
)
2.360
-0.000 (-0.00%)
Official Closing Price
Updated: 8:00 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Can-Fite Biopharma Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
CAN-FITE BIOPHARMA GAINS ANALYST "BUY" DISTINCTION AND SIGNS NEW DISTRIBUTION AGREEMENTS FOR ITS LEAD DRUG CANDIDATES
May 12, 2021
Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver...
Via
Benzinga
Can-Fite to Present at Benzinga’s Global Small Cap Conference on May 13, 2021
May 06, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite’s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021
April 29, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
April 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...
Via
Benzinga
Can-Fite Expands Mid-Stage COVID-19 Study To Europe
April 22, 2021
Can-Fite BioPharma Ltd (NYSE: CANF) has expanded its Phase 2 COVID-19 study of Piclidenoson to two European countries, Romania and Bulgaria. The randomized,...
Via
Benzinga
Exposures
COVID-19
Can-Fite Expands its Phase II COVID-19 Study to Europe
April 22, 2021
From
Can-Fite BioPharma Ltd
Via
Business Wire
Can-Fite Starts Preclinical Studies Required By FDA, EMA For Two Lead Drug Candidates Registration Filing
April 20, 2021
Can-Fite BioPharma (NYSE: CANF) has initiated a series of preclinical studies required by regulators to support potential marketing registration filings for...
Via
Benzinga
Exposures
Product Safety
Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates
April 20, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.